- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | The observation status for OncoZenge AB is removed | 364 | GlobeNewswire | On January 22, 2026, the financial instruments in OncoZenge AB (the "Company") were given observation status with reference to uncertainty in respect of the issuer's financial position.
On September... ► Artikel lesen | |
| 23.09. | STOCKHOLM CORPORATE FINANCE: OncoZenge announces the final outcome of the rights issue | 2 | Cision News | ||
| 22.09. | OncoZenge AB: OncoZenge announces the final outcome of the rights issue | 310 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 18.09. | OncoZenge AB: OncoZenge announces the preliminary outcome of the rights issue | 553 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 03.09. | Listing of subscription rights and paid subscription shares of OncoZenge AB | 361 | GlobeNewswire | With effect from September 04, 2026, the subscription rights in OncoZenge AB will be traded on First North Growth Market. Trading will continue up until and including September 15, 2026.
... ► Artikel lesen | |
| 31.08. | OncoZenge AB: OncoZenge AB advances global patent strategy for BupiZenge with filings in 17 markets | 373 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that it has entered the national and regional phase of its Patent Cooperation Treaty (PCT) application for BupiZenge in 17 jurisdictions.... ► Artikel lesen | |
| 31.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.08.2026 | 465 | Xetra Newsboard | Das Instrument 92Y NO0012477704 JACKTEL AS EQUITY wird cum Kapitalmassnahme gehandelt am 31.08.2026 und ex Kapitalmassnahme am 01.09.2026 The instrument 92Y NO0012477704 JACKTEL AS EQUITY is traded... ► Artikel lesen | |
| 28.08. | OncoZenge AB: Fourth tranche payment deadline expires without full payment from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd | 504 | GlobeNewswire (Europe) | Following the expiry of the payment deadline, OncoZenge AB (publ) ("OncoZenge" or the "Company") provides the following update on the status of the fourth tranche. The extended payment deadline for... ► Artikel lesen | |
| ONCOZENGE Aktie jetzt für 0€ handeln | |||||
| 28.08. | OncoZenge AB: OncoZenge secures bridge financing of SEK 2.0 million ahead of rights issue | 476 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company" or "OncoZenge") announces today, on 28 August 2026, that the Company has entered into a bridge loan agreement with John Haurum in the amount of SEK 2.0 million in... ► Artikel lesen | |
| 27.08. | OncoZenge AB: Investor withholds remaining payment for fourth tranche resulting in short-term liquidity shortfall | 270 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company") has received a letter from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (the "Investor") with information that the Investor will withhold payment of... ► Artikel lesen | |
| 27.08. | OncoZenge AB: OncoZenge AB Interim Report January 1 - June 30, 2026 | 186 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the second quarter of 2026. The company reports receipt of regulatory approval to initiate patient recruitment... ► Artikel lesen | |
| 25.08. | OncoZenge AB: OncoZenge resolves on a rights issue of approximately SEK 33.3 million and publishes preliminary financial information for the second quarter of 2026 | 638 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 07.08. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 455 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 17.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 381 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 07.07. | OncoZenge AB: OncoZenge AB Announces Enrollment of First Patient in Pivotal Phase III BEAM-Pain Trial of BupiZenge | 1.148 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announces that the first patient has been... ► Artikel lesen | |
| 03.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Subscription Proceeds | 362 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the subscription proceeds of approximately SEK 15.1 million in... ► Artikel lesen | |
| 02.06. | OncoZenge AB: OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici | 266 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that the second milestone payment has been received from the Company's licensee, Molteni Farmaceutici.
The company announced on March... ► Artikel lesen | |
| 27.05. | OncoZenge AB: Bulletin From The Annual General Meeting Of OncoZenge | 248 | GlobeNewswire (Europe) | At the annual general meeting ("AGM") of OncoZenge AB (publ) held on 27 May 2026, the following principal resolutions were adopted, in accordance with the proposals submitted by the Board of Directors... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge | 828 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announced that it has received regulatory... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge AB Interim Report January 1 - March 31, 2026 | 280 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the first quarter of 2026. The company reports progress with European authorities expecting regulatory approval... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 35,255 | +0,31 % | Novo Nordisk muss zittern: Eli Lilly vor Milliardenchance: Neue Abnehmpille nimmt wichtige EU-Hürde! | Eli Lillys Abnehmpille Foundayo nimmt eine wichtige EU-Hürde. Die mögliche Zulassung verschärft den Milliardenwettbewerb mit Novo Nordisk Enthaltene Werte: US5324571083,DK0062498333Den vollständigen... ► Artikel lesen | |
| ASTRAZENECA | 152,35 | -0,94 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| CAMURUS | 59,85 | -1,07 % | Novo Nordisk legt weitere 1,3 Milliarden Dollar auf den Tisch - warum Eli Lilly und Co. schon um die nächste Milliardenplattform kämpfen | ||
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| MERCK KGAA | 143,70 | -1,81 % | Milliarden-Hammer: Merck geht aufs Ganze: Dieser Milliarden-Deal könnte alles verändern! | © Foto: Arne Dedert/dpaMerck übernimmt Silence Therapeutics für 1,3 Milliarden US-Dollar. Mit innovativer Gen-Technologie will der Pharmakonzern neue Wachstumsfelder erschließen Enthaltene Werte: DE0006599905Den... ► Artikel lesen | |
| BAYER | 44,050 | -0,36 % | Buy or Goodbye?: Tesla, Totalenergies, Nestle und Bayer - Die Analystenstimmen des Tages | © Foto: Ding Ting/XinHua/dpaTesla, Totalenergies, Nestle und Bayer: Die wichtigsten Analysten-Updates im Überblick Enthaltene Werte: DE000BAY0017,FR0000120271,CH0038863350,US88160R1014Den vollständigen... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 50,13 | +0,22 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| IAMBIC THERAPEUTICS | 14,520 | -1,02 % | Biotech an der Börse: Iambic-IPO bringt 150 Millionen USD für Krebsmedikamente | Das US-Biotechunternehmen Iambic setzt bei neuen Krebsmedikamenten auf künstliche Intelligenz. Mit dem frischen Börsenkapital will es klinische Studien voranbringen und seine Forschungstechnik ausbauen.... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,130 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| GENERATE BIOMEDICINES | 12,800 | +0,08 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,460 | +0,10 % | Stifel reiterates Buy rating on LB Pharmaceuticals stock at $53 | ||
| KARDIGAN | 12,740 | 0,00 % | Baird stuft Kardigan mit "Outperform" ein - Kursziel 43 US-Dollar | ||
| OMNIAB | 4,770 | 0,00 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| BRIGHT MINDS BIOSCIENCES | 52,50 | -0,36 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| APNIMED | 18,540 | 0,00 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen |
Das Unternehmen ONCOZENGE AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-1,75 %) liegt der Kurs bei 0,281 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOZENGE AB finden Sie auf Wallstreet Online.